BEAM Projected Dividend Yield
Beam Therapeutics Inc ( NASDAQ : BEAM )Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. Co.'s suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. 21 YEAR PERFORMANCE RESULTS |
BEAM Dividend History Detail BEAM Dividend News BEAM Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |